Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.73 |
| ▸ | NPC1 | O15118 | 2/20 | 0.68 |
| ▸ | RAB9A | P51151 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.65 |
| ▸ | ANPEP | P15144 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | CASR | P41180 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2913379 | 0.87 | ALDH1A1 (0.75) | ALDH1A1NPC1RAB9AKMT2AANPEP | |
| SCHEMBL18251704 | 0.85 | ALDH1A1 (0.55) | ALDH1A1NPC1RAB9AKMT2A | |
| SCHEMBL12884462 | 0.84 | ALDH1A1 (0.62) | ALDH1A1NPC1RAB9AKMT2AANPEP | |
| SCHEMBL2749188 | 0.83 | ALDH1A1 (0.66) | ALDH1A1NPC1RAB9AKMT2AANPEP | |
| SCHEMBL21435278 | 0.82 | ALDH1A1 (0.68) | ALDH1A1NPC1RAB9AKMT2AANPEP | |
| SCHEMBL9424898 | 0.82 | ALDH1A1 (0.73) | ALDH1A1NPC1RAB9AKMT2AANPEP | |
| SCHEMBL27802239 | 0.82 | ALDH1A1 (0.59) | ALDH1A1NPC1RAB9AKMT2AANPEP | |
| SCHEMBL1433979 | 0.81 | NPC1 (0.72) | ALDH1A1NPC1RAB9AKMT2AHTT | |
| SCHEMBL30858769 | 0.81 | NPC1 (1.00) | ALDH1A1NPC1RAB9AKMT2AANPEP | |
| SCHEMBL12757441 | 0.80 | LMNA (0.63) | ALDH1A1NPC1RAB9AKMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9656962-B2 | Ring-contracted morphinans and the use thereof | PURDUE PHARMA L.P. (US) | 2017-05-23 | — | — | US | disclosed |
| US-9616064-B2 | Rho kinase inhibitors and methods of use | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-9616064-B2 | Rho kinase inhibitors and methods of use | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-20160340316-A1 | RING-CONTRACTED MORPHINANS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2016-11-24 | — | — | US | disclosed |
| US-9302985-B2 | Benzyl sulfonamide derivatives as RORc modulators | GENENTECH, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-20140179689-A1 | NOVEL RHO KINASE INHIBITORS AND METHODS OF USE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140163110-A1 | BENZYL SULFONAMIDE DERIVATIVES AS RORc MODULATORS | GENENTECH, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| EP-1586552-B1 | PROCESS FOR PRODUCING BENZYLAMINE DERIVATIVE | IHARA CHEMICAL IND CO (JP) | 2010-08-25 | — | — | EP | disclosed |
| US-7326813-B2 | Process for producing benzylamine derivative | IHARA CHEMICAL INDUSTRY (JP) | 2008-02-05 | — | — | US | disclosed |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | PHARMACIA CORPORATION | 2007-04-05 | — | — | US | disclosed |
| US-20060155141-A1 | Process for producing benzylamine derivative | ITO AKINORI | 2006-07-13 | — | — | US | disclosed |
| EP-1586552-A1 | PROCESS FOR PRODUCING BENZYLAMINE DERIVATIVE | IHARA CHEMICAL INDUSTRY Co., Ltd. (JP) | 2005-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060155141-A1 | Process for producing benzylamine derivative | BRD7, BRD1, BRD2 | ALDH1A1 2660/4885NPC1 3303/4885RAB9A 730/4885 |
| US-20140179689-A1 | NOVEL RHO KINASE INHIBITORS AND METHODS OF USE | ROCK1, ROCK2, RHOA | ALDH1A1 3573/4885NPC1 2279/4885RAB9A 321/4885 |
| US-20140163110-A1 | BENZYL SULFONAMIDE DERIVATIVES AS RORc MODULATORS | RORC, RORA, RORB | ALDH1A1 1126/4885NPC1 2444/4885RAB9A 1181/4885 |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | MAPK1, MAPK3, MAPK4 | ALDH1A1 1079/4885NPC1 4880/4885RAB9A 2090/4885 |
| US-20160340316-A1 | RING-CONTRACTED MORPHINANS AND THE USE THEREOF | OPRM1, OPRL1, OPRK1 | ALDH1A1 657/4885NPC1 3408/4885RAB9A 779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.